Diaromatic compounds derived from a salicylic unit and their use in
human and veterinary medicine and in cosmetics
    4.
    发明授权
    Diaromatic compounds derived from a salicylic unit and their use in human and veterinary medicine and in cosmetics 失效
    衍生自水杨酸单元的二芳族化合物及其在人兽药和化妆品中的应用

    公开(公告)号:US5654331A

    公开(公告)日:1997-08-05

    申请号:US450078

    申请日:1995-05-25

    摘要: Diaromatic compounds, characterised in that they correspond to the following general formula: ##STR1## in which: R.sub.1 is --CH.sub.3, --CH.sub.2 OH, --COR.sub.8 or --CH.sub.2 OCOR.sub.9, R.sub.8 is H, OH, --OR.sub.10, --N(rr') or alkyl, R.sub.10 is alkyl, alkenyl, aryl or aralkyl, r and r' being H, alkyl, aryl, aralkyl, etc., r and r' together form a heterocycle, R.sub.9 is alkyl, alkenyl or a sugar residue, R.sub.2 and R.sub.3 are --OR.sub.11 or --OCOR.sub.11, R.sub.11 is H, alkyl, fluoroalkyl, aryl or aralkyl, R.sub.3 in addition being H, R.sub.4 is H, OH, alkyl, alkoxy, F, Cl or --CF.sub.3, R.sub.5 and R.sub.7 are H, OH, alkoxy, .alpha.-substituted alkyl or .alpha.,.alpha.'-disubstituted alkyl, etc., R.sub.6 is H, OH, alkyl, alkoxy, cycloalkyl, etc., R.sub.5 and R.sub.7 cannot simultaneously be OH or alkoxy and R.sub.4, R.sub.5, R.sub.6 and R.sub.7 cannot simultaneously be H, R.sub.5 and R.sub.6 or R.sub.6 and R.sub.7 can form, with the aromatic ring, a ring with 5 or 6 members, X is chosen from amongst:(i) --C(R.sub.13 R.sub.14)--C(R.sub.16 R.sub.18)--W--, (ii) --C(R.sub.14)--W--R.sub.16 C(R.sub.18 R.sub.19)--, (iii) --C(R.sub.13 R.sub.14)--C(R.sub.15 R.sub.16)--C(R.sub.18 R.sub.20)--, (iv) --CR.sub.17 .dbd.CR.sub.21 --C(R.sub.13 R.sub.14)--in which:W is O, --NR.sub.12 or S(O).sub.n, n=0, 1 or 2, R.sub.13, R.sub.15 and R.sub.20 are H, --OR.sub.11, --OCOR.sub.11 etc., R.sub.14, R.sub.16, R.sub.18 and R.sub.19 are H, aralkyl, alkyl, etc., when X is (i) R.sub.13 and R.sub.14 can form .dbd.N--OR.sub.11 or .dbd.N--OCOR.sub.11, when X is (iii) or (iv), R.sub.14, R.sub.16 and R.sub.18 are also --OR.sub.11 or --OCOR.sub.11, or R.sub.13, R.sub.14 or R.sub.15, R.sub.16 taken together can form .dbd.NOR.sub.11 or .dbd.N--OCOR.sub.11, R.sub.12 is H, alkyl, aralkyl, alkenyl, alkynyl or fluoroalkyl, R.sub.17 is H, hydroxyl, alkyl or alkoxy, R.sub.21 is H or alkyl, and the salts of the compounds of formula (I).

    摘要翻译: 其特征在于它们对应于以下通式:其中:R1是-CH3,-CH2OH,-COR8或-CH2OCOR9,R8是H,OH,-OR10,-N(rr ')或烷基,R 10是烷基,烯基,芳基或芳烷基,r和r'是H,烷基,芳基,芳烷基等,r和r'一起形成杂环,R 9是烷基,烯基或糖残基, R2和R3是-OR11或-OCOR11,R11是H,烷基,氟烷基,芳基或芳烷基,R3是H,R4是H,OH,烷基,烷氧基,F,Cl或-CF3,R5和R7是H ,OH,烷氧基,α-取代的烷基或α,α'-二取代的烷基等,R6是H,OH,烷基,烷氧基,环烷基等,R5和R7不能同时为OH或烷氧基,R4,R5, R6和R7不能同时为H,R5和R6或R6和R7可以与芳环形成具有5或6个成员的环,X选自:(i)-C(R 13 R 14)-C(R 16 R 18) -W-,(ii)-C(R14)-W-R16C(R18R19) - ,(iii)-C(R13R14)-C(R15R16)-C(R18R20) - ,(iv)-CR17 = CR21-C (R13R14) - 其中:W为O ,-NR 12或S(O)n,n = 0,1或2,R 13,R 15和R 20为H,-OR 11,-OCOR 11等,R 14,R 16,R 18和R 19为H,芳烷基,烷基等。 当X是(i)R 13和R 14可以形成= N-OR 11或= N-OCOR 11时,当X是(iii)或(iv)时,R 14,R 16和R 18也是-OR 11或-OCOR 11或R 13,R 14 或R 15,R 16一起形成= NOR11或= N-OCOR11,R12为H,烷基,芳烷基,烯基,炔基或氟代烷基,R17为H,羟基,烷基或烷氧基,R21为H或烷基, 式(I)的化合物。

    Method for chemical separation of cannabinoids

    公开(公告)号:US11351476B2

    公开(公告)日:2022-06-07

    申请号:US16781330

    申请日:2020-02-04

    发明人: Alex Goodnough

    摘要: A method for chemical separation of cannabinoids includes: (i) providing a starting organic solvent solution that contains a mixture of cannabinoid acids, (ii) using an aqueous basic solution to remove a portion of the cannabinoid acids from the mixture of cannabinoid acids in the starting organic solvent solution by converting the portion of the cannabinoid acids to cannabinoid carboxylate salts that solubilize in the an aqueous basic solution, (iii) separating the aqueous basic solution in (ii) from the starting organic solvent, (iv) combining the aqueous solution from (iii) with new organic solvent to produce a combined solution, (v) acidifying the combined solution to extract the cannabinoid acids from the aqueous solution to the organic solvent, (vi) separating the organic solvent of (v) from the aqueous solution, and (vii) evaporating the organic solvent of (vi) to leave product cannabinoid acids.